{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T21:15:01Z","timestamp":1767906901638,"version":"3.49.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.cllc.2023.11.014","type":"journal-article","created":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T07:26:58Z","timestamp":1701761218000},"page":"91-99","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Trial Design and Optimal Determination of CNS Activity of Small Molecule Targeted Therapy in NSCLC"],"prefix":"10.1016","volume":"25","author":[{"given":"Elaine M.","family":"Jennings","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. Ross","family":"Camidge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shirish","family":"Gadgeel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Barker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2023.11.014_bib0001","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.1016\/S1470-2045(14)71180-5","article-title":"Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin","volume":"16","author":"Oser","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2023.11.014_bib0002","first-page":"45","article-title":"Epidemiology of lung cancer","volume":"25","author":"Thandra","year":"2021","journal-title":"Contemp Oncol (Pozn)"},{"key":"10.1016\/j.cllc.2023.11.014_bib0003","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.lungcan.2013.08.004","article-title":"Identification of subgroup patients with stage IIIB\/IV non-small cell lung cancer at higher risk for brain metastases","volume":"82","author":"Hsiao","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2023.11.014_bib0004","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/BF02782192","article-title":"Long-term survival with metastatic cancer to the brain","volume":"17","author":"Hall","year":"2000","journal-title":"Med Oncol"},{"key":"10.1016\/j.cllc.2023.11.014_bib0005","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1097\/JTO.0000000000000669","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitors for non-small-cell lung cancer patients with leptomeningeal carcinomatosis","volume":"10","author":"Liao","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2023.11.014_bib0006","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.lungcan.2012.03.002","article-title":"Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group","volume":"77","author":"Umemura","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2023.11.014_bib0007","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11060-004-8093-6","article-title":"Brain metastases: epidemiology and pathophysiology","volume":"75","author":"Gavrilovic","year":"2005","journal-title":"J Neurooncol"},{"key":"10.1016\/j.cllc.2023.11.014_bib0008","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/neuonc\/noz246","article-title":"Exclusion of patients with brain metastases from cancer clinical trials","volume":"22","author":"Patel","year":"2020","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.cllc.2023.11.014_bib0009","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1016\/S1470-2045(17)30693-9","article-title":"Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group","volume":"19","author":"Camidge","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2023.11.014_bib0010","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1016\/S1470-2045(15)70057-4","article-title":"Response assessment criteria for brain metastases: proposal from the RANO group","volume":"16","author":"Lin","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2023.11.014_bib0011","doi-asserted-by":"crossref","first-page":"e396","DOI":"10.1016\/S1470-2045(13)70311-5","article-title":"Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group","volume":"14","author":"Lin","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2023.11.014_bib0012","doi-asserted-by":"crossref","first-page":"e407","DOI":"10.1016\/S1470-2045(13)70308-5","article-title":"Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group","volume":"14","author":"Lin","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2023.11.014_bib0013","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC","volume":"382","author":"Ramalingam","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2023.11.014_bib0014","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non\u2013small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2023.11.014_bib0015","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.semcancer.2019.09.015","article-title":"Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer","volume":"61","author":"Harrison","year":"2020","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.cllc.2023.11.014_bib0016","doi-asserted-by":"crossref","first-page":"4502","DOI":"10.1002\/cncr.27409","article-title":"Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer","volume":"118","author":"Doebele","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.cllc.2023.11.014_bib0017","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.lungcan.2015.01.020","article-title":"Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers","volume":"88","author":"Rangachari","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2023.11.014_bib0018","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2023.11.014_bib0019","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/annonc\/mdv270","article-title":"First-line erlotinib versus gemcitabine\/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study","volume":"26","author":"Wu","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2023.11.014_bib0020","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2023.11.014_bib0021","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.2018.77.9363","article-title":"CNS efficacy of osimertinib in patients with T790M-positive advanced non-small-cell lung cancer: data from a randomized phase III trial (AURA3)","volume":"36","author":"Wu","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2023.11.014_bib0022","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/annonc\/mdx820","article-title":"CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials","volume":"29","author":"Goss","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2023.11.014_bib0023","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.jtho.2019.12.113","article-title":"Osimertinib for patients with leptomeningeal metastases associated with EGFR T790M-positive advanced NSCLC: the AURA leptomeningeal metastases analysis","volume":"15","author":"Ahn","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"suppl 17; abstr LBA3","key":"10.1016\/j.cllc.2023.11.014_bib0024","article-title":"Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB\u2013IIIA non-small cell lung cancer (NSCLC)","volume":"41","author":"Herbst","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2023.11.014_bib0025","doi-asserted-by":"crossref","first-page":"5216","DOI":"10.1158\/1078-0432.CCR-09-0802","article-title":"Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population","volume":"15","author":"Rodig","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2023.11.014_bib0026","doi-asserted-by":"crossref","first-page":"610","DOI":"10.6004\/jnccn.2021.5020","article-title":"Non\u2013small cell lung cancer: recommendations for biomarker testing and treatment","volume":"19","author":"Aisner","year":"2021","journal-title":"J Natl Comprehensive Cancer Network"},{"key":"10.1016\/j.cllc.2023.11.014_bib0027","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1200\/JCO.2012.44.5353","article-title":"ALK in lung cancer: past, present, and future","volume":"31","author":"Shaw","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2023.11.014_bib0028","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2016.68.4639","article-title":"Pooled analysis of CNS Response to alectinib in two studies of pretreated patients with ALK-positive non-small-cell lung cancer","volume":"34","author":"Gadgeel","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2023.11.014_bib0029","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1093\/annonc\/mdy405","article-title":"Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study","volume":"29","author":"Gadgeel","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2023.11.014_bib0030","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11523-020-00702-4","article-title":"Brain penetration of lorlatinib: cumulative incidences of CNS and Non-CNS progression with lorlatinib in patients with previously treated ALK-positive non-small-cell lung cancer","volume":"15","author":"Bauer","year":"2020","journal-title":"Target Oncol"},{"key":"10.1016\/j.cllc.2023.11.014_bib0031","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1200\/JCO.2009.22.6993","article-title":"Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK","volume":"27","author":"Shaw","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2023.11.014_bib0032","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S1470-2045(18)30649-1","article-title":"Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study","volume":"19","author":"Solomon","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2023.11.014_bib0033","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2023.11.014_bib0034","article-title":"Phase II study of lorlatinib in patients with anaplastic lymphoma kinase\u2013positive lung cancer and CNS-specific relapse","volume":"6","author":"Dagogo-Jack","year":"2022","journal-title":"JCO Precision Oncol"},{"key":"10.1016\/j.cllc.2023.11.014_bib0035","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1200\/JCO.2011.35.6345","article-title":"ROS1 rearrangements define a unique molecular class of lung cancers","volume":"30","author":"Bergethon","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2023.11.014_bib0036","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S1470-2045(19)30690-4","article-title":"Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials","volume":"21","author":"Drilon","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2023.11.014_bib0037","article-title":"Long-term efficacy and safety of entrectinib in ROS1 fusion-positive NSCLC","volume":"3","author":"Drilon","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.cllc.2023.11.014_bib0038","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS9141","article-title":"A randomized phase 3 study of entrectinib versus crizotinib in patients (pts) with locally advanced\/metastatic ROS1 fusion-positive (fp) NSCLC with or without baseline CNS metastases (mets)","volume":"40","author":"Dingemans","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2023.11.014_bib0039","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1758835920928634","article-title":"Current management of RET rearranged non-small cell lung cancer","volume":"12","author":"Stinchcombe","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.cllc.2023.11.014_bib0040","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/j.jtho.2018.07.004","article-title":"Frequency of brain metastases and multikinase inhibitor outcomes in patients with RET-rearranged lung cancers","volume":"13","author":"Drilon","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2023.11.014_bib0041","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2005653","article-title":"Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer","volume":"383","author":"Drilon","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2023.11.014_bib0042","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1158\/1078-0432.CCR-21-0800","article-title":"Intracranial efficacy of selpercatinib in RET fusion-positive non-small cell lung cancers on the LIBRETTO-001 trial","volume":"27","author":"Subbiah","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2023.11.014_bib0043","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211019675","article-title":"Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program","volume":"13","author":"Illini","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.cllc.2023.11.014_bib0044","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2309457","article-title":"First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion\u2013Positive NSCLC","author":"Zhou","year":"2023","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.cllc.2023.11.014_bib0045","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S1470-2045(21)00247-3","article-title":"Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1\/2 study","volume":"22","author":"Gainor","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2023.11.014_bib0046","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1016\/j.cllc.2021.06.005","article-title":"Central nervous system response to selpercartinib in patient with RET-rearranged non-small cell lung cancer after developing leptomeningeal disease on pralsetinib","volume":"23","author":"Tsui","year":"2022","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.cllc.2023.11.014_bib0047","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/nrm1261","article-title":"Vande Woude GF. Met, metastasis, motility and more","volume":"4","author":"Birchmeier","year":"2003","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.cllc.2023.11.014_bib0048","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1200\/JCO.2015.63.4600","article-title":"MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression","volume":"34","author":"Awad","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2023.11.014_bib0049","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature13385","article-title":"Comprehensive molecular profiling of lung adenocarcinoma","volume":"511","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.cllc.2023.11.014_bib0050","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1158\/2159-8290.CD-15-0285","article-title":"Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors","volume":"5","author":"Frampton","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.cllc.2023.11.014_bib0051","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41591-019-0716-8","article-title":"Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration","volume":"26","author":"Drilon","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.cllc.2023.11.014_bib0052","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1158\/2159-8290.CD-14-1467","article-title":"Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping","volume":"5","author":"Paik","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.cllc.2023.11.014_bib0053","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa2002787","article-title":"Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer","volume":"383","author":"Wolf","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2023.11.014_bib0054","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.jtho.2021.01.1605","article-title":"A phase 2 study of capmatinib in patients with MET-altered lung cancer previously treated with a MET inhibitor","volume":"16","author":"Dagogo-Jack","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2023.11.014_bib0055","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa2004407","article-title":"Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations","volume":"383","author":"Paik","year":"2020","journal-title":"N Engl J Med"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730423002577?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730423002577?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T12:31:30Z","timestamp":1736857890000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730423002577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S1525730423002577"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2023.11.014","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trial Design and Optimal Determination of CNS Activity of Small Molecule Targeted Therapy in NSCLC","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2023.11.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}